

# Mirena & Metformin in Endometrial Cancer

Andreas Obermair

Queensland Centre for Gynaecological Cancer

Brisbane, Australia

# Oral Progestin vs. IUD


## Oral Studies



## Intrauterine Devices



# Schema: Mirena ± Metformin ± Weight Loss



# feMME Trial - Eligibility

## Eligibility:

- *Complex Endometrial Hyperplasia with atypia OR*
- *Grade 1 EAC – avoid enrolling patients with advanced disease who need expedited surgery*
- Patients at **high surgical risks** or **wish to retain fertility**
- BMI > 30 kg/m<sup>2</sup>
- CT scan: absence of extrauterine disease
- Myometrial invasion <50% (MRI)
- Serum CA125 ≤30 U/mL



# feMME (AUS) to treat EHA/EAC

- Three-arm, prospective, multi-institutional study
- **Intervention:** Mirena vs. Mirena + Metformin vs. Mirena + lifestyle intervention (weight loss, exercise)
- **Outcomes:** Complete Pathological Response rate at 6 months
- Commence: July 2013
- Target N= 165
- Contact: QLD Centre for Gynaecological Cancer –
  - [obermair@powerup.com.au](mailto:obermair@powerup.com.au)